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OBJECTIVES The aim of this study was to investigate in dialysis patients with symptomatic heart failure
New York Heart Association (NYHA) functional class II or III whether the addition of
carvedilol to conventional therapy is associated with beneficial effects on cardiac architecture,
function and clinical status.
BACKGROUND Congestive heart failure (CHF) in chronic hemodialyzed patients, particularly when associ-
ated with dilated cardiomyopathy, represents an ominous complication and is an independent
risk factor for cardiac mortality.
METHODS We enrolled 114 dialysis patients with dilated cardiomyopathy. All patients were treated with
carvedilol for 12 months in a double-blind, placebo-controlled, randomized trial. The patients
underwent M-mode and two-dimensional echocardiography at baseline, 1, 6 and 12 months
after the randomization. Each patient’s clinical status was assessed using an NYHA functional
classification that was determined after 6 and 12 months of treatment.
RESULTS Carvedilol treatment improved left ventricular (LV) function. In the active-treatment group,
the increase in LV ejection fraction (from 26.3% to 34.8%, p , 0.05 vs. basal and placebo
group) and the reduction of both LV end-diastolic volume (from 100 ml/m2 to 94 ml/m2,
p , 0.05 vs. basal and placebo group) and end-systolic volume (from 74 ml/m2 to 62 ml/m2,
p , 0.05 vs. basal and placebo group) reached statistical significance after six months of
therapy, compared with baseline and corresponding placebo values, and they remained
constant at one year of treatment (p , 0.05 vs. basal and placebo group). The clinical status
of patients, assessed by NYHA functional classification, improved during the treatment
period. Moreover, at the end of the trial, there were no patients in NYHA functional class IV
in the carvedilol group, compared with 5.9% of the patients in the placebo arm.
CONCLUSIONS One year of therapy with carvedilol in dialysis patients with CHF and dilated cardiomyopathy
reduces LV volumes and improves LV function and clinical status. (J Am Coll Cardiol 2001;
37:407–11) © 2001 by the American College of Cardiology
Cardiac involvement is a common finding in dialysis pa-
tients, accounting for 40% of deaths in this patient popu-
lation (1,2). In this regard, congestive heart failure (CHF)
in chronic hemodialyzed patients, particularly when associ-
ated with dilated cardiomyopathy, represents an ominous
complication and is an independent risk factor for cardiac
mortality. Carvedilol, a third-generation beta-adrenergic
blocking agent, has recently been shown to reduce mortality
in patients with heart failure (3).
Thus, the poor outcome of dialysis patients with dilated
cardiomyopathy on one hand—and the beneficial effects
documented by several controlled studies employing carve-
dilol in CHF on the other hand—prompted us to evaluate
the effects of carvedilol on left ventricular (LV) structure,
function and clinical status in dialysis patients with CHF
and dilated cardiomyopathy. Carvedilol was administered
for 12 months in a double-blind, placebo-controlled fash-
ion, in addition to the standard background therapy.
METHODS
Patients. From February 1996 to December 1998 we
recruited 132 patients (89 men, 43 women, mean age
55.1 6 7.6 years) with uremia on periodic hemodialysis
treatment and dilated cardiomyopathy: 68% had a history of
ischemic heart disease (defined as a documented history of
myocardial infarction [MI], typical angina, an exercise
electrocardiogram positive for ischemia or angiographic
evidence of coronary disease), 24% had a history of arterial
hypertension, while 8% had non-specified histories. All
patients were symptomatic for heart failure (New York
Heart Association [NYHA] functional class II to III) for at
least one year, with an LV ejection fraction (LVEF) ,0.35
at echocardiography. To be included in the study, patients
had to be clinically stable with no change in their usual
medications in the last two weeks and should not have
required intravenous inotropic drug therapy nor experienced
weight changes for at least 48 h before the enrollment
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(.2.5 kg compared with the “dry weight”). Exclusion
criteria included: current NYHA functional class IV; heart
rate (HR) ,50 beats/min; sick sinus syndrome; first degree
atrioventricular block with a PQ interval .0.24 s; second-
or third-degree heart block (unless controlled by a pacemak-
er); documented episodes of sustained ventricular tachycar-
dia (.30 s, .120 beats/min); systolic blood pressure (BP)
,90 mm Hg; stroke; acute MI; unstable angina; coronary
angioplasty or aortocoronary bypass surgery in the three
previous months; uncorrected valvular heart disease; active
myocarditis; obstructive and restrictive cardiomyopathy;
current treatment with verapamil, alpha/beta adrenergic
agonists or antagonists; chronic obstructive airways disease;
hepatic disease (serum transaminase .3 times normal); drug
or alcohol abuse; or any other life-threatening noncardiac
disease.
All patients were on digitalis; 128 patients (96.9%) were
also receiving angiotensin-converting enzyme (ACE) inhib-
itors; four patients (3.1%) who were intolerant of the
ACE-inhibitors received angiotensin II receptor antago-
nists; 32 (25%) patients were taking nitrates.
All patients were dialyzed four times a week for a mean
time of 210 6 30 min, with a middle quote blood of 260 6
20 ml/min, using a cuprophan hollow-fiber hemodialyzer by
1.3 to 1.8 m2 of surface and 7.5 m of thickness. A
personalized bath of dialysis was used, with variable con-
centration of potassium between 2 and 3.5 mEq/L. The
concentration of sodium was variable between 144 and
150 mEq/L in relation to the BP. Monitors were used for
computerized checking of ultrafiltration and real-time mon-
itoring of the loss of the weight, so as to have an exact and
constant control of the weight reduction per hour. Further-
more, HR and BP were checked. The “dry-weight” of all
patients was stable for at least one month.
Design and study treatment. Potentially eligible patients
were enrolled in a parallel, double-blind, placebo-
controlled, randomized treatment protocol. During a pre-
liminary “run-in” phase, all patients received carvedilol
(3.125 mg twice a day) for two weeks in order to determine,
before randomization, which patients were unable to toler-
ate low doses of carvedilol. Patients able to tolerate the
initial dose were then randomly assigned to receive either
placebo or carvedilol (1:1 randomization) in double-blind
fashion, while maintaining their background therapy un-
changed. During the titration period, the dose of carvedilol
was doubled at two-week intervals and then increased to a
target dose of 25 mg twice a day. When the dose increase
was not tolerated for the appearance of adverse reactions
such as HR ,50 beats/min or arterial hypotension (BP
,90/60 mm Hg), it was temporarily halved, then again
increased the following week. The same protocol was
followed for patients randomized to the placebo treatment;
it was administered in tablets similar to the study drug. At
the end of the up-titration phase, the therapy with carvedilol
or placebo was maintained for 12 months (maintenance
phase), during which time carvedilol was administered at
the maximum dose of 25 mg twice a day or to the highest
dose tolerated. Concomitant therapy with digitalis, ACE
inhibitors, angiotensin II receptor antagonists and nitrates
was maintained, although the dosage was adjusted accord-
ing to the clinical conditions of the patient or to the
appearance of side effects possibly related to these drugs.
End points and assessment. The patients were checked
with daily medical examinations during titration and every
other day during the maintenance phase in concomitance
with dialysis.
The end points considered were as follows: 1) changes in
LV end-diastolic volume (LVEDV) and LV end-systolic
volume (LVESV) and LVEF at 1, 6 and 12 months after
randomization and 2) changes in symptoms of heart failure
6 and 12 months after the randomization.
One, 6 and 12 months after the beginning of the
maintenance phase, a clinical-instrumental assessment was
performed in all patients, including a complete M-mode
and two-dimensional echocardiography. The clinical status
of the patients was also assessed using an NYHA functional
classification that was determined at 6 and 12 months of
treatment.
Echocardiographic assessment. The patients admitted to
the randomization phase were subjected to baseline
M-mode and two-dimensional echocardiography upon ad-
mission and at 1, 6 and 12 months after the randomization.
The assessment was performed in all patients on the day
after dialysis, between 24 and 30 h after completion of the
dialysis session, by operators who were not aware of the
clinical conditions of the patients. The assessment was
performed after 5 min of rest, with the subject in left lateral
decubitus using a Hewlett Packard Sonos 1000 machine
equipped with a 2.5 MHz probe. As an index of systolic
function, LVEF, LVEDV and LVESV were measured
according to the Simpson’s rule (4). The echocardiographic
exams were made on videotapes and controlled by medical
doctors not aware of the clinical conditions of patients.
The patients were informed in detail of the formalities
and finality of the study. All patients provided written
informed consent to participate. The institutional commit-
tee on human research approved the study protocol.
Among the 132 patients eligible for the inclusion in the
trial, 18 were excluded during the run-in phase. Thus, 114
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
BP 5 blood pressure
CHF 5 congestive heart failure
HR 5 heart rate
LV 5 left ventricle, left ventricular
LVEDV 5 left ventricular end-diastolic volume
LVEF 5 left ventricular ejection fraction
LVESV 5 left ventricular end-systolic volume
MI 5 myocardial infarction
NYHA 5 New York Heart Association
408 Cice et al. JACC Vol. 37, No. 2, 2001
Carvedilol in Dialysis Patients With Dilated Cardiomyopathy February 2001:407–11
patients, whose clinical characteristics are displayed in Table
1, started the maintenance phase.
Statistics. All values are given as mean 6 standard devia-
tion. Statistical analysis was performed using a PC com-
puter. Between-group comparisons were performed using
the two-way analysis of variance with treatment as one factor
and time as the other factor. One-way analysis of variance was
used for the other comparisons. When appropriate, compari-
sons to determine the significance of changes within the same
group over time and between groups at each time point were
performed with the Newman-Keul test after the samples were
tested for normal distribution. Noncontinuous variables, like
NYHA class, were analyzed with the chi-square test. A value
of p , 0.05 was considered significant.
RESULTS
Dropout patients. Of the 132 patients entering the run-in
phase, 18 (13.6%) were excluded due to side effects: hypo-
tension (n 5 3), dizziness (n 5 1), bronchospasm (n 5 5),
bradycardia (n 5 4), worsening heart failure (n 5 4) and
protocol violation (n 5 1). Of the 114 patients starting the
titration phase, no one was excluded. Of the 114 patients
entering the maintenance phase, 11 (9.6%) dropped out of
the study: four patients in the carvedilol group dropped
out—one for the appearance of hypotension, one for bra-
dycardia, one for second-degree heart block and one because
of acute MI; seven patients in the placebo group dropped
out—three for worsening heart failure, two because of
sudden death, one because of acute MI and one because of
death from refractory hyperpotassiemia. One hundred and
three patients completed the study.
Mortality was not significantly different between the two
groups at one year (0/58 in carvedilol group vs. 3/56 in
placebo group; p . 0.05).
Clinical and echocardiographic parameters. The princi-
pal clinical and echocardiographic parameters in the placebo
and carvedilol groups are summarized in Table 2. Heart rate
decreased significantly after one month of treatment com-
pared with baseline and corresponding placebo values; such
reduction was sustained at 6 and 12 months. Systolic and
diastolic systemic BP decreased significantly after one
month of treatment compared with baseline and corre-
sponding placebo values, and such reduction remained
significant until the end of the trial. A new statistical
significance was reached at 6 and at 12 months, compared
with the control at one month and corresponding placebo
values.
The increase in LVEF and the reduction of both
LVEDV and LVESV reached statistical significance after
six months of therapy, compared with baseline, compared
with control at one month and compared with correspond-
ing placebo values, and remained constant at one year of
treatment.
NYHA classification. The clinical status of patients, as-
sessed by NYHA functional classification, improved signif-
icantly during the treatment period (p , 0.05) (Table 3):
three (5.6%) patients treated with carvedilol were in NYHA
functional class I after six months, increasing to four (7.4%)
after 12 months; patients in NYHA functional class II
increased from 18 (33.3%) at baseline to 34 (63%) at six
months and to 35 (64.8%) at 12 months. Conversely,
Table 1. Clinical Characteristics of 114 Study Patients
Carvedilol
(n 5 58)
Placebo
(n 5 56)
Age (yrs) 54.9 6 8.1 55.2 6 7.1
Men/women 32/26 37/19
Body surface area (m2) 1.80 6 0.25 1.84 6 0.22
Duration of dialysis (months) 85.6 6 14.9 81.7 6 14.2
Interdialitic weight increase (kg) 2.5 6 0.7 2.8 6 0.8
Heart rate (beat/min) 93.3 6 10.9 92.6 6 11.8
Systolic blood pressure (mm Hg) 133.9 6 7.7 134.5 6 9.3
Diastolic blood pressure (mm Hg) 75.4 6 5.8 74.7 6 6.3
Previous myocardial infarction (%) 41 39
Current treatment:
ACE inhibitors (%) 98 99
Angiotensin II receptor antagonists (%) 2 1
Digitalis (%) 100 100
Nitrates (%) 20 22
NYHA classification
I (%) 0 0
II (%) 34.5 42.9
III (%) 65.5 57.1
IV (%) 0 0
LVEDV (ml/m2) 100 6 9 97 6 8
LVESV (ml/m2) 74 6 8 72 6 9
LVEF (%) 26 6 8 26 6 8
ACE 5 angtiotensin-converting enzyme; LVEDV 5 left ventricular end-diastolic
volume; LVEF 5 left ventricular ejection fraction; LVESV 5 left ventricular
end-systolic volume.
Table 2. Blood Pressure and Echocardiographic Parameters in the Carvedilol and Placebo Groups
Carvedilol Placebo
Basal 1 Month 6 Months 12 Months Basal 1 Month 6 Months 12 Months
HR (beats/min) 93 6 11 69 6 7*† 69 6 7*† 69 6 7*† 93 6 12 92 6 12 91 6 12 92 6 12
SBP (mm Hg) 134 6 8 124 6 7*† 123 6 7*†‡ 123 6 8*†‡ 135 6 9 134 6 9 133 6 10 133 6 11
DBP (mm Hg) 75 6 6 68 6 6*† 67 6 6*†‡ 67 6 6*†‡ 75 6 6 74 6 6 75 6 6 73 6 6
LVEDV (ml/m2) 100 6 9 99 6 8 94 6 8*†‡ 94 6 4*†‡ 97 6 8 97 6 8 99 6 6 98 6 6
LVESV (ml/m2) 74 6 8 72 6 8 62 6 8*†‡ 62 6 8*†‡ 72 6 9 72 6 8 72 6 8 72 6 8
LVEF (%) 26 6 8 27 6 7 35 6 11*†‡ 36 6 11*†‡ 26 6 8 26 6 8 27 6 8 26 6 8
*p , 0.05 vs. basal; †p , 0.05 vs. placebo; ‡p , 0.05 vs. control at 1 month.
DBP 5 diastolic blood pressure; HR 5 heart rate; LVEDV 5 left ventricular end-diastolic volume; LVEF 5 left ventricular ejection fraction; LVESV 5 left ventricular
end-systolic volume; SBP 5 systolic blood pressure.
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patients in NYHA functional class III decreased from 36
(66.7%) at baseline to 17 (31.4%) at six months and to 15
(27.8%) at 12 months of treatment; there were no patients
in NYHA functional class IV in the carvedilol group. By
contrast, in the placebo group there was a worsening of the
NYHA functional classification; there was no patient in
NYHA functional class I, and patients in NYHA functional
class II decreased from 22 (44.9%) at baseline to 19 (38.8%)
at six months, with no change at 12 months. Patients in
NYHA functional class III increased from 27 (55.1%) at
baseline to 28 (57.1%) at six months and to 27 (55.1%) at 12
months. Patients in NYHA functional class IV increased
from two (4.1%) at six months to three (6.1%) at 12 months.
DISCUSSION
The current data demonstrate for the first time that a
12-month therapy with carvedilol reduces LV volumes and
improves cardiac function and the clinical status of dialysis
patients with dilated cardiomyopathy. Such beneficial effects
were significant after six months of therapy, persisted until
the end of the trial, and were independent of the genesis of
heart failure.
Use of beta-blockers in dialysis patients. Although the
use of beta-blockers in dialysis patients with CHF is
justified in view of the peculiar neurohumoral status of these
patients (5–7), no controlled study has yet addressed their
safety and potential usefulness in such a clinical setting.
Previous studies from our group have recently documented
the efficacy and safety of carvedilol in CHF patients (8) and
in the management of systemic hypertension and “silent”
angina in chronic hemodialyzed patients (9–11). Among
other beta-blocking agents, carvedilol possesses a favorable
profile, considering its prevalent hepatic metabolism that
does not require dose adjustment in the case of impaired
renal function (12).
The presence of dilated cardiomyopathy in our patient
population represents a further indication for the use of a
beta-blocker (13,14). In fact, LV dilation is an independent
predictor of mortality in chronic hemodialyzed patients that
exhibits a two-year survival rate of 67% when an echocar-
diographic diagnosis of dilated cardiomyopathy is made,
compared with a 90% survival rate observed in the control
population with a normal echocardiogram.
On the other hand, carvedilol is the only beta-blocker
approved for treatment of chronic heart failure in the U.S.
and most other countries (3).
Our patient population consisted of subjects with
moderate-to-severe heart failure (EF 26.3 6 7.6% in the
carvedilol group; 26.1 6 7.9% in the placebo group) and
symptomatic NYHA functional class II to III, with preva-
lent ischemic etiology. There were no patients in NYHA
functional class IV, except at the end of the trial in the
placebo group.
Dropout patients. There were 18/132 patients during the
run-in phase and 4/58 patients during the maintenance
phase who were unable to tolerate the drug (20.5%),
compared with 7/56 placebo patients (12.5%). Although the
incidence of dropout was considerable in this study, most of
them occurred during the run-in phase. Once the patients
entered the titration phase, there were no dropouts. During
the maintenance phase, there were only four dropouts
(6.9%) in the carvedilol group, compared with seven drop-
outs (12.5%) in the placebo group.
Effects of carvedilol on cardiac function and on NYHA
classification. The time-course of LV structural and func-
tional changes in this study was evaluated by means of
two-dimensional echocardiography (15). Significant reduc-
tion of LV volumes and improvement in LVEF were
evident after six-month carvedilol treatment and persisted
until the end of the trial.
The magnitude of change in LVEF, LVEDV and
LVESV observed in this study is reminiscent of that
described in previous trials using beta-blockers for patients
with CHF (16–21). The change in volumes and EF are
generally higher than those achieved with ACE inhibitor
drugs (22) that are known to stabilize rather than reduce LV
volumes in the setting of CHF (23).
It should be stressed that the structural and functional
changes observed with noninvasive techniques were associ-
ated with significant improvements in the clinical status in
this study. In fact, almost 30% of the patients on carvedilol
shifted from NYHA class III to NYHA class II, and no
patient progressed to NYHA class IV, compared with 6.1%
of the patients on placebo in NYHA class IV after 12
months of treatment. This finding is congruent with previ-
ous clinical trials in nonuremic patients with CHF, in whom
beta-blockers were able to slow the disease progression
(16–21).
A potential limitation of this study was the lack of an
Table 3. Assessment of NYHA Class Over the Treatment Period
Carvedilol (54 Patients) Placebo (49 Patients)
Basal 6 Months 12 Months Basal 6 Months 12 Months
Class I 0 (0%) 3 (5.6%)* 4 (7.4%)* 0 (0%) 0 (0%) 0 (0%)
Class II 18 (33.3%) 34 (63%)* 35 (64.8%)* 22 (44.9%) 19 (38.8%) 19 (38.8%)
Class III 36 (66.7%) 17 (31.4%)* 15 (27.8%)* 27 (55.1%) 28 (57.1%) 27 (55.1%)
Class IV 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (4.1%) 3 (6.1%)
*P , 0.05 versus basal.
NYHA 5 New York Heart Association.
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accurate assessment of the exercise capacity and the subjec-
tive nature of the NYHA class assignment. However, in all
the study participants we assessed the NYHA functional
class, which in several previous studies has been successfully
employed to monitor the clinical status in CHF clinical
trials.
Conclusions. In conclusion, one year of therapy with
carvedilol in dialysis patients with CHF and dilated cardio-
myopathy reduced LV volumes and improved LV function
and clinical status. Future survival studies are needed to
evaluate whether the beneficial effects observed with one
year of carvedilol therapy will eventually translate into
decreased mortality in dialysis patients with CHF and
dilated cardiomyopathy (24).
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